What the FDA labels say about taking them together
Dolutegravir and fosamprenavir
Dolutegravir's FDA label of May 22, 2026 names fosamprenavir in its drug interactions section, and fosamprenavir's label names dolutegravir too. The dolutegravir label: “Adjust dose of TIVICAY to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of TIVICAY or TIVICAY PD to twice daily. …”
Check it at the source: the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY); the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.).
What does the dolutegravir label say about fosamprenavir?
Dolutegravir label, drug interactionsConcomitant Drug Class/Drug Name: Protease inhibitors: Fosamprenavir/ritonavir a Tipranavir/ritonavir a; Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Adjust dose of TIVICAY to twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of TIVICAY or TIVICAY PD to twice daily (Tables,, and). Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. b
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
What does the fosamprenavir label say about dolutegravir?
Fosamprenavir label, drug interactionsConcomitant Drug Class/Drug Name: HIV integrase inhibitor: Dolutegravir; Effect on Concentration of Amprenavir or Concomitant Drug: Fosamprenavir/ ritonavir: ↓ Dolutegravir; Clinical Comment: The recommended dose of dolutegravir is 50 mg twice daily when coadministered with fosamprenavir/ritonavir. Use an alternative combination where possible in patients with known or suspected integrase inhibitor resistance.
Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dolutegravir | Fosamprenavir | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $77.64 per tablet 50 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once